<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935479</url>
  </required_header>
  <id_info>
    <org_study_id>AK159 I-4</org_study_id>
    <nct_id>NCT01935479</nct_id>
  </id_info>
  <brief_title>A Phase I Study of AK159 in Healthy Postmenopausal Women</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asahi Kasei Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asahi Kasei Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the pharmacokinetics, safety, and tolerability
      of AK159 administered to healthy postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts: Part 1 and Part 2. The Part 1 is a single-center,
      randomized, 2-way crossover study that investigates the pharmacokinetics, safety, and
      tolerability of teriparatide after a single dose of AK159 (5 levels) and estimates the
      relative bioavailability of AK159 with subcutaneous teriparatide acetate in healthy
      post-menopausal women.

      The Part 2 is a multiple-center, randomized, double-blind, positive- and placebo-controlled,
      parallel study that compares the pharmacokinetics, bone makers, safety, and tolerability of
      teriparatide after a weekly doses of AK159 (4 levels) for 6 weeks with placebo and a weekly
      doses of subcutaneous teriparatide acetate in healthy post-menopausal women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of teriparatide</measure>
    <time_frame>up to 6 hours after single and repeated administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of teriparatide</measure>
    <time_frame>up to 6 hours after single and repeated administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events and Incidence of adverse events</measure>
    <time_frame>up to 7 weeks after the initial administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bone turnover markers from baseline</measure>
    <time_frame>up to 7 weeks after the initial administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual assessment of the application site</measure>
    <time_frame>up to 7 weeks after the initial administration</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Residual teriparatide in the patch after application</measure>
    <time_frame>up to 6 weeks after the initial administration</time_frame>
  </other_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>AK159 SD 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of AK159 dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK159 SD 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of AK159 dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK159 SD 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of AK159 dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK159 SD 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of AK159 dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN-10-T SD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administration of teriparatide acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK159 MD 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration of AK159 dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK159 MD 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration of AK159 dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK159 MD 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration of AK159 dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK159 MD 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration of AK159 dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN-10-T MD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple administration of MN-10-T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple administration of placebo AK159</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK159</intervention_name>
    <description>transdermal administration of teriparatide acetate</description>
    <arm_group_label>AK159 SD 1</arm_group_label>
    <arm_group_label>AK159 SD 2</arm_group_label>
    <arm_group_label>AK159 SD 3</arm_group_label>
    <arm_group_label>AK159 SD 4</arm_group_label>
    <arm_group_label>AK159 MD 1</arm_group_label>
    <arm_group_label>AK159 MD 2</arm_group_label>
    <arm_group_label>AK159 MD 3</arm_group_label>
    <arm_group_label>AK159 MD 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MN-10-T</intervention_name>
    <description>subcutaneous administration of teriparatide acetate</description>
    <arm_group_label>MN-10-T SD</arm_group_label>
    <arm_group_label>MN-10-T MD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo AK159</description>
    <arm_group_label>Placebo MD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal ethnic Japanese women

          -  At least 45 years of age at the time consent is obtained

          -  Give voluntary consent in writing with a sufficient understanding of the study.

        Exclusion Criteria:

          -  Clinical abnormality identified in the laboratory tests

          -  Weight &lt; 40.0 kg

          -  Body mass index &lt; 17.5 or &gt;=30.5

          -  History of disease of the kidneys, liver, heart, brain, or other organ that makes them
             ineligible as subjects

          -  Previously received radiation treatment potentially affecting bone

          -  Clinical abnormality identified in the 12-lead ECGs performed at the study center
             during the screening period

          -  Systolic blood pressure &lt; 90 mmHg

          -  Serum calcium level exceeding 10.4 mg/dL

          -  History of contact dermatitis or skin disease potentially compromising study
             evaluation

          -  Used drugs which impact bone metabolism in the 8-week period preceding investigational
             product administration

          -  Used a bisphosphonate

          -  Used a teriparatide product
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumida</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AK159, teriparatide acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

